2 nd aasm
play

2 nd AASM (25-28 Feb 2017 Isfahan, Iran) Saturday 25 th Feb 2017 - PowerPoint PPT Presentation

Feb 04, 2023 •322 likes •395 views

Program at a glance 2 nd AASM (25-28 Feb 2017 Isfahan, Iran) Saturday 25 th Feb 2017 ( 8:30-18:30) 8.30 -9:30 Registration Session 1 9:30 -10:00 Quran & Opening ceremony Time Title of oral presentation Speakers (country) Chairs

  1. Program at a glance 2 nd AASM (25-28 Feb 2017 Isfahan, Iran)

  2. Saturday 25 th Feb 2017 ( 8:30-18:30) 8.30 -9:30 Registration Session 1 9:30 -10:00 Quran & Opening ceremony Time Title of oral presentation Speakers (country)  Chairs Symposium 1 Tuberculosis in Children  Ali Akbar Velayati (Iran) 10:00-10:20 Tuberculosis in children Ali Akbar Velayati (Iran)  Fadila Boulahbal (Algeria) Incidence of tuberculosis among children living in contact with smear-positive tuberculosis:  Margareta Eriksson(Sweden) 10:20- 10:40 Djohar Hannoun (Algeria) Advantages and limits of the Quantiferon TB gold in tube test  Zahra Hasan (Pakistan) 10:40-11:00 Benefits and challenges of molecular diagnostics for childhood tuberculosis • Maria Cristina Gutierrez (Spain) David.L.Dolinger(Switzerland) What can we learn from the past? —A pediatrician’s view 11:00-11:20 Margareta Eriksson (Sweden) 11:20-11:40 Update on multidrug-resistant tuberculosis in children Hendrik Simon Schaaf (South Africa) Effective testing for pulmonary tuberculosis using Xpert MTB/RIF assay for stool  Coordinator 11:40-12:00 Zahra Hasan (Pakistan) specimens in immunocompetent Pakistani children Maria Cristina Gutierrez (Spain) Contribution of the Xpert MTB/RIF assay to the diagnosis of pulmonary tuberculosis in a 12:00-12:15 Abigail Ayorinde (Gambia) West African childhood tuberculosis clinic 12:15-12:30 The difficulties of childhood tuberculosis diagnosis Amel Meriem Djouahra ( Algeria) Session 2 12:30 – 12:40 Question time 12:40 – 14:00 Lunch Time Title of oral presentation Speakers (country) Symposium 2 Threats to achieving tuberculosis control program Complex emergencies in the Eastern Mediterranean Region: Impact on tuberculosis control Akihiro Seita (Japan) 14: 00 – 14:15  Chairs Collaboration between tuberculosis control programs and the action plan for tackling Rumina Hasan ( Pakistan) 14:15 – 14:30  Alimuddin Zumla (UK) antimicrobial resistance: An opportunity in the Eastern Mediterranean Region  Majid Marjani (Iran) Babar Mumtaz (UK)  Rumina Hasan ( Pakistan) 14: 30 – 14:45 TB: Is urbanization a threat or an opportunity ?  Bhaskar Chinnaian Chetty Harinath Situational analysis of tuberculosis control programs in the Eastern Mediterranean Region: Samiha Baghdadi (Egypt ) (India 14:45- 15:00  Daniela Cirillo (Italy ) Gaps and solutions Tuberculosis in vulnerable populations in Eastern Mediterranean Region — Implications for Sadia Shakoor (Pakistan) 15:00 15:15 control  Coordinator HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12- Payam Tabarsi (Iran)  Sadia Shakoor ( Pakist an) 15:15-15:30 year study Nationwide HIV-, MDR-TB survey in Japan and collaborative study in the Philippines Toshio Hattori (Japan) 15-30:15:45 Role of socio-demographical factors on tuberculosis outcome in Yemen Amer Hayat Khan (Malaysia) 15:45-16:00 _ 16:00- 16:10 Question time

  3. Sunday 26 th Feb 2017 (8:30-18:30 ) Session 3 Time Title of oral presentation Speakers (country) New Approaches for TB – treatment Symposium 3  Chairs Host-directed therapies for multidrug resistant tuberculosis 8:45- 9:00 Matthew Bates (UK)  Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis Matthew Bates (UK) 9:00-9:15 Aliaksandr Skrahin (Belarus)  Robin M. Warren (South Africa) Application of highly portable MinION nanopore sequencing technology for the monitoring of  Malin Ridell (Sweden) 9:15- 9:30 Matthew Bates (UK) nosocomial tuberculosis infection  Blessina Kumar (India) Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit 9:30-9:45 Delia Goletti (Italy)  Poopak Farnia (Iran) Next-generation sequencing-based user-friendly platforms for drug-resistant tuberculosis diagnosis: A 9:45- 10:00 David Lee Dolinger (Switzerland) promise for the near future  Coordinator  Kouassi Raymond N’GUESSAN ( Côte d’Ivoire) New approaches in drug treatment for tuberculosis: Inhalation using liposomes only a future vision or 10:00- 10:15 Lars-Olof Larsson (Sweden) soon in clinical practice? 10:15 – 10:20 Question time Session 4 10:20 – 10:30 Coffee – break Time Title of oral presentation Speakers (country) Symposium 4 Tuberculosis Reaching consensus on drug resistance conferring mutations 10:30-10:45 Daniela Maria Cirillo (Italy)  Chairs Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs 10:45-11:00 Yi Hu (China) on treatment outcomes in multidrug-resistant tuberculosis in China  Daniela Maria Cirillo (Italy) Investigation of isoniazid and ethionamide cross-resistance by whole genome  Sven Hoffner (Sweden) sequencing and association with poor treatment outcomes of multidrug-resistant  11:00-11:15 Lesibana Anthony Malinga (South Africa) Dick Van Soolingen (Netherlands) tuberculosis patients in South Africa  Bushra Ali (Pakistan) Genetic diversity, transmission dynamics, and drug resistance of  Jalaleddin Ghanavi (Iran) JOAO RUBEN LUCAS MOTA PERDIGAOPORTUGAL 11:15-11:30 DIAS JORDAO (Portugal) Mycobacterium tuberculosis in Luanda, Angola 11:30-11:40 Best approaches to drug-resistance surveillance at the country level Andrea Maurizio Cabibbe (Italy) Screening new tuberculosis patients in Mali for rifampicin resistance at 2 months 11:40-11:50 Bassirou Diarra (Mali)  Coordinator 11:50-12:00 Use of WGS in Mycobacterium tuberculosis routine diagnosis Daniela Maria Cirillo (Italy)  David Benjamin Pokam Thumamo (Cameroon) The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa Géraldine Daneau (Belgium) 12:00- 12-10 present a concomitant resistance to pyrazinamide Multi-Drug Resistant Mycobacterium tuberculosis and Associated Risk Factors in the 12:10-12:20 Girma Mulisa Misgana (Ethiopia ) Oromia Region of Ethiopia Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis 12:20-12:30 Mulualem Tadesse (Ethiopia) from pulmonary tuberculosis patients in Southwest Ethiopia Ethambutol-resistance testing by mutation detection using MTBDRsl 12:30- 12:40 Hasmik Margaryan (Armenia)

  4. Sunday 26 th Feb 2017 (8:30-18:30 ) 12:40 – 12:50 Question time Session 5 12:50 – 14:00 Lunch Time Title of oral presentation Speakers (country) Symposium 5 Clinical Tuberculosis  Chairs 14:00 – 14:20 What is in a cough? Kevin Fennelly (USA)  Ali Akbar Velayati (Iran) New options in Tuberculosis Care: Visions for the future are crucial for 14:20 – 14:40  Malin Ridell (Sweden) Matthew Bates (UK) controlling the disease  Bhupendra Nath Tripathi (India) Personalized information system for the control of tuberculosis in resource-  14:40 – 14:55 Igor Mokrousov (Russia) David Benjamin Pokam Thumamo (Cameroon) limited settings: A simplistic proposal approach  Pere-Joan Cardona (Spain) Ravindra Kumar Dewan (India) 14:55:15:10 Thoracic Surgical Interventions for DR-TB and their results  Coordinator Usefulness of pulmonary artery diameter in diagnosing pulmonary 15:10-15:25 Seyed Mohammadreza Hashemian (Iran) hypertension in patients admitted to tuberculosis intensive care unit  Sadia Shakoor (Pakistan) Muhammad Irfan (Pakistan) 15:25-15:45 Post-tuberculosis pulmonary function and noninfectious pulmonary disorders Emotional distress patients with several types of tuberculosis. A pilot study 15:45-16:00 Bruno Peixoto (Portugal) with patients from the Sanatorium Hospital of Huambo 16:00-16:10 Question time

More recommend